We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -74.00 | -0.62% | 11,952.00 | 11,950.00 | 11,954.00 | 12,144.00 | 11,910.00 | 12,070.00 | 524,411 | 13:32:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.23 | 185.96B |
From Apr 2019 to Apr 2024
LONDON--AstraZeneca PLC (AZN) said Tuesday that the first randomized Phase III trial of its Tagrisso drug had demonstrated better results than chemotherapy for some types of lung cancer.
The results showed the drug had the potential to replace chemotherapy as the standard treatment for certain patients, the pharmaceutical giant said.
Tagrisso is a once-daily tablet approved in the European Union, the U.S., Japan and Canada and a number of other countries as the first treatment for patients with certain types of lung cancer.
AstraZeneca shares at 0940 GMT were down 20 pence, or 0.5%, at 40.14 pounds($42.73), valuing the company at GBP50.77 billion.
-Write to Razak Musah Baba at razak.baba@wsj.com
(END) Dow Jones Newswires
December 06, 2016 05:10 ET (10:10 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
